Evidence map›Paper›PMID 24809912›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome.

Bianca De Filippis, Paola Nativio, Alessia Fabbri, Laura Ricceri, Walter Adriani, Enza Lacivita, Marcello Leopoldo, Francesca Passarelli, Andrea Fuso, Giovanni Laviola

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bianca De FilippisDepartment of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Paola NativioDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alessia FabbriDepartment of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy.
Laura RicceriDepartment of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Walter AdrianiDepartment of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Enza LacivitaDepartment of Pharmacy, University of Bari 'A Moro', Bari, Italy.
Marcello LeopoldoDepartment of Pharmacy, University of Bari 'A Moro', Bari, Italy.
Francesca PassarelliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Andrea Fuso1] Department of Psychology, Section of Neuroscience, Sapienza University of Rome, Rome, Italy [2] European Center for Brain Research (CERC)/IRCCS Santa Lucia Foundation, Rome, Italy.
Giovanni LaviolaDepartment of Cell Biology and Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
Istituto Superiore di Sanità · ITSapienza University of Rome · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms. Mutations in the methyl CpG-binding protein 2 gene (MECP2) cause >95% of classic cases, and currently there is no cure for this devastating disorder. The serotonin receptor 7 (5-HT7R) is linked to neuro-physiological regulation of circadian rhythm, mood, cognition, and synaptic plasticity. We presently report that 5-HT7R density is consistently reduced in cortical and hippocampal brain areas of symptomatic MeCP2-308 male mice, a RTT model. Systemic repeated treatment with LP-211 (0.25 mg/kg once/day for 7 days), a brain-penetrant selective 5-HT7R agonist, was able to rescue RTT-related defective performance: anxiety-related profiles in a Light/Dark test, motor abilities in a Dowel test, the exploratory behavior in the Marble Burying test, as well as memory in the Novelty Preference task. In the brain of RTT mice, LP-211 also reversed the abnormal activation of PAK and cofilin (key regulators of actin cytoskeleton dynamics) and of the ribosomal protein (rp) S6, whose reduced activation in MECP2 mutant neurons by mTOR is responsible for the altered protein translational control. Present findings indicate that pharmacological targeting of 5-HT7R improves specific behavioral and molecular manifestations of RTT, thus representing a first step toward the validation of an innovative systemic treatment. Beyond RTT, the latter might be extended to other disorders associated with intellectual disability.

Indexed as

Actin Depolymerizing FactorsAnimalsAnxietyBrainDisease Models, AnimalExploratory BehaviorMaleMice, Inbred C57BLMice, TransgenicMotor Activityp21-Activated KinasesPiperazinesPsychotropic DrugsReceptors, SerotoninRett Syndromerho GTP-Binding ProteinsActin Depolymerizing FactorsN-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamidep21-Activated KinasesPiperazinesPsychotropic DrugsReceptors, Serotoninrho GTP-Binding ProteinsRibosomal Protein S6ribosomal protein S6, mouseserotonin 7 receptorSerotonin Receptor Agonists

Identifiers

PMID24809912
PMCPMC4207333
OpenAlexW2017708470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.